All In Biotech

Drug Trial Radar · NCT04619316

Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition

Enhancing Radioiodine Incorporation Into Radio Iodine Refractory Thyroid Cancers With MAPK Inhibition: A Single Center Pilot Study

Last checked: Nov 19, 2026Latest source record: Jun 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

70

Planned (sponsor's estimate)

Start

Feb 5, 2018

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
University Hospital, EssenAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective interventional trial that aims to restore iodine incorporation in tumoral lesions of patients with unresectable, radioiodine-refractory thyroid cancer.

Conditions

  • Metastatic Thyroid Cancer

Interventions

  • Trametinib 2 MG [Mekinist]Drug

    Monotherapy with Trametinib is given in patients with BRAF wildtype.

  • Trametinib 2 MG [Mekinist] and Dabrafenib 75 MG (2-0-2) [Tafinlar]Drug

    Combination therapy is given in patients with BRAF V600E mutation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of patients with sufficiently increased tumoral iodine incorporationTime frame: At the time point of 123I whole-body scintigraphy, 3 weeks after the start of redifferentiation therapy

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Manuel M. Weber

    Essen, North Rhine-Westphalia, Germany · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.